Literature DB >> 3142936

Influence of heat treatment on FVIII:C recovery from freeze dried cryoprecipitate.

A G Benny1, P A Ockelford, A S Johns, R H Scott, D G Woodfield, E W Berry.   

Abstract

A standard lyophilised triple cryoprecipitate preparation, stabilised by the addition of Synthamin 17, was heat treated at 60 degrees C for 48 hours. The total protein content, factor VIII concentration, and factor VIII recovery were not affected by the heat treatment procedure. Heat treatment did not influence the reconstitution characteristics of the freeze dried preparation and there were no side effects during or after administration. The mean in vivo rise of factor VIII from infused heat treated triple cryoprecipitate was 2.5 (SD 0.9)%/unit/kg with a half life of 13.1 (3.1) hours. These results compare favourably with those obtained using non-heated triple cryoprecipitate. Cryoprecipitate can be heat treated without adversely influencing factor VIII recovery, and the ability to prepare a heat treated cryoprecipitate means that a small pool high yield factor VIII preparation can again be used in routine clinical practice.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3142936      PMCID: PMC1141649          DOI: 10.1136/jcp.41.9.945

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  11 in total

1.  An artificial 'haemophilic' plasma for one-stage factor-VIII assay.

Authors:  V Chantarangkul; G I Ingram; M B Thorn; S C Darby
Journal:  Br J Haematol       Date:  1978-11       Impact factor: 6.998

2.  THE IN VIVO LONGEVITY OF ANTIHAEMOPHILIC FACTOR (FACTOR VIII).

Authors:  C F ABILDGAARD; J A CORNET; E FORT; I SCHULMAN
Journal:  Br J Haematol       Date:  1964-04       Impact factor: 6.998

3.  [Rapid physiological coagulation method in determination of fibrinogen].

Authors:  A CLAUSS
Journal:  Acta Haematol       Date:  1957-04       Impact factor: 2.195

4.  Controlled pore glass factor VIII concentrate: influence of heat treatment.

Authors:  P A Ockelford; A G Benny; E W Berry; A S Johns; D G Woodfield
Journal:  Pathology       Date:  1987-01       Impact factor: 5.306

5.  Stabilising effect of aminoacids on factor VIII in lyophilised cryoprecipitate.

Authors:  J Margolis; M Eisen
Journal:  Lancet       Date:  1984-12-08       Impact factor: 79.321

6.  The influence of pH on heat denaturation of anti-haemophilic cryoprecipitate.

Authors:  O H Skjønsberg; K Gravem; P Kierulf; A Vaeret; H C Godal
Journal:  Thromb Res       Date:  1987-07-15       Impact factor: 3.944

7.  Prepooled cryoprecipitate for treatment of hemophilia A.

Authors:  J E Menitove; J A Spero; W A Richards; J H Lewis; R R Montgomery; J C Gill; U Hasiba; D V Wheeler; J A Sherwin; S Russell-Vaskov; R A Marlar; N G Maxwell; R H Aster
Journal:  Transfusion       Date:  1983 May-Jun       Impact factor: 3.157

8.  Freeze dried cryoprecipitate: a clinical evaluation.

Authors:  H Hambley; J F Davidson; I D Walker; M Small; C R Prentice
Journal:  J Clin Pathol       Date:  1983-05       Impact factor: 3.411

9.  Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes.

Authors:  Z M Ruggeri; P M Mannucci; R Lombardi; A B Federici; T S Zimmerman
Journal:  Blood       Date:  1982-06       Impact factor: 22.113

10.  Preparation of pooled cryoprecipitate for treatment of hemophilia A in a home care program.

Authors:  K J Smith; P A Hodges
Journal:  Transfusion       Date:  1984 Nov-Dec       Impact factor: 3.157

View more
  1 in total

1.  Separation of antihemophilic factor VII from human plasma by column chromatography.

Authors:  V M Baikar; M V Kamath; C Vishwanathan; A M Varadkar; S E Bharmal
Journal:  Indian J Clin Biochem       Date:  2003-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.